Regado Biosciences Raised to “Outperform” at Zacks (RGDO)
Regado Biosciences (NASDAQ:RGDO) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research note issued to investors on Thursday. The firm currently has a $1.20 target price on the stock. Zacks‘s target price would suggest a potential upside of 6.19% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Jefferies Group downgraded shares of Regado Biosciences from a “buy” rating to a “hold” rating in a research note on Monday. They now have a $1.50 price target on the stock, down previously from $7.50. Separately, analysts at Deutsche Bank downgraded shares of Regado Biosciences from a “buy” rating to a “hold” rating in a research note on Monday. They now have a $2.00 price target on the stock, down previously from $14.00. Finally, analysts at Cowen and Company downgraded shares of Regado Biosciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 13th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company’s stock. Regado Biosciences currently has an average rating of “Hold” and an average target price of $4.96.
Shares of Regado Biosciences (NASDAQ:RGDO) traded down 2.65% on Thursday, hitting $1.10. The stock had a trading volume of 505,871 shares. Regado Biosciences has a one year low of $1.09 and a one year high of $14.10. The stock’s 50-day moving average is $2.59 and its 200-day moving average is $6.21. The company’s market cap is $37.0 million.
Regado Biosciences (NASDAQ:RGDO) last announced its earnings results on Monday, August 11th. The company reported ($0.63) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.51) by $0.12. Analysts expect that Regado Biosciences will post $-2.38 EPS for the current fiscal year.
Regado Biosciences, Inc is a biopharmaceutical company focused on the discovery and development of actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.